Acute pericardial effusion representing the TNF-α-mediated severe inflammation but not the coronary artery outcome of Kawasaki disease

References

• Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271–6.
   PubMed Web of Science ®Google Scholar
• Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, et al. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 in acute Kawasaki disease. Circulation 2002;105:766–69.
   PubMed Web of Science ®Google Scholar
• Hamada H, Terai M, Honda T, Kohno Y. Marked pleural and pericardial effusion with elevated vascular endothelial growth factor production. A common complication of Kawasaki disease. Pediatr Int 2005;47:112–14.
   Google Scholar
• Chantepie A, Mauran P, Lusson JR, Vaillant MC, Bozio A. Cardiovascular complications of Kawasaki syndrome: results of a French multicenter study. Arch Pediatr 2001;8:713–19.
   Google Scholar
• Salince P, Pietrogrande MC, Barbier P, Ghiglia S, Laicini E, Fesslova V. Cardiovascular abnormalities in Kawasaki disease. An Italian prospective study. Cardiologia 1998;43:1367–74.
   Google Scholar
• Ülger Z, Levent E, Özdemir R, Ozyürek AR. Kawasaki disease recurrence with cardiac tamponade. Anadolu Kardiyol Derg 2005;5:234–6.
   Google Scholar
• Gidding SS, Duffy CE, Pajcic S, Berdusis K, Shulman ST. Usefulness of echocardiographic evidence of pericardial effusion and mitral regurgitation during the acute stage in predicting development of coronary arterial aneurysms in the late stage of Kawasaki disease. Am J Cardiol 1987;60:76–9.
   Google Scholar
• Lega JC, Bozio A, Cimaz R, Veyrier M, Floret D, Ducreux C, et al. Extracoronary echocardiographic findings as predictors of coronary artery lesions in the initial phase of Kawasaki disease. Arch Dis Child 2013;98:97–102.
   PubMed Web of Science ®Google Scholar
• Nishio H, Kanno S, Onoyama S, Ikeda K, Tanaka T, Kusuhara K, et al. Nod1 ligands induce site-specific vascular inflammation. Arterioscler Thromb Vasc Biol 2011;31:1093–9.
   PubMed Web of Science ®Google Scholar
• Johnson JN, Cetta F. Pericardial diseases. In: Allen HD, Driscoll DJ, Shaddy RE, Feltes TF, editors. Moss and Adams’ heart disease in infants, children and adolescents: including the fetus and young adult, 8th edn, vol. II. Philadelphia, USA: Lippincott Williams & Wilkins, 2013:1350–62.
   Google Scholar
• JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008) - digest version. Circ J 2010; 74:1989–2020.
   PubMed Web of Science ®Google Scholar
• Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149:237–40.
   PubMed Web of Science ®Google Scholar
• Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007;166:131–7.
   PubMed Web of Science ®Google Scholar
• Takanashi J, Shirai K, Sugawara Y, Okamoto Y, Obonai T, Terada H. Kawasaki disease complicated by mild encephalopathy with a reversible splenial lesion (MERS). J Neurol Sci 2012;315:167–9.
   Google Scholar
• Muneuchi J, Kusuhara K, Kanaya Y, Ohno T, Furuno K, Kira R, et al. Magnetic resonance studies of brain lesions in patients with Kawasaki disease. Brain Dev 2006;28:30–3.
   Google Scholar
• Shikama N, Terano T, Hirai A. A case of rheumatoid pericarditis with high concentrations of interleukin-6 in pericardial fluid. Heart 2000;83:711–12.
   PubMed Web of Science ®Google Scholar
• Karatolios K, Moosdorf R, Maisch B, Pankuweit S. Cytokines in pericardial effusion of patients with inflammatory pericardial disease. Mediators Inflamm 2012;2012:382082.
   Google Scholar
• Duncombe AS, Brenner MK. Is circulating tumor necrosis factor bioactive? N Engl J Med 1988;319:1227–8.
   PubMed Web of Science ®Google Scholar
• Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptor. J Biol Chem 1990;265:1531–6.
   PubMed Web of Science ®Google Scholar
• Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H. T cell-mediated lethal shock triggered in mice by the superantigen Staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 1992;175:91–8.
   PubMed Web of Science ®Google Scholar
• Bette M, Schäfer MKH, van Rooijen N, Weihe E, Fleischer B. Distribution and kinetics of superantigen-induced cytokine gene expression. J Exp Med 1993;178:1531–9.
   Google Scholar
• Hui-Yuen JS, Duong TT, Yeung RS. TNF-α is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176: 6294–301.
   PubMed Web of Science ®Google Scholar
• Lau AC, Duong TT, Ito S, Yeung RS. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum 2008;58:854–63.
   PubMed Web of Science ®Google Scholar
• Ohno T, Igarashi H, Inoue K, Akazawa K, Joho K, Hara T: Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 2000;159:424–9.
   Google Scholar
• Kuo HC1, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. Acta Paediatr 2010; 99:1578–83.
   Google Scholar
• Gruys E, Toussaint MJ, Niewold TA, Koopmans SJ, van Dijk E, Meloen RH. Monitoring health by values of acute phase proteins. Acta Histochem 2006;108:229–32.
   PubMed Web of Science ®Google Scholar
• Oishi T, Fujieda M, Shiraishi T, Ono M, Inoue K, Takahashi A, et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ J 2008;72: 850–2.
   PubMedGoogle Scholar
• Morceau F, Dicato M, Diederich M. Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis. Mediators Inflamm 2009;2009:405016.
   PubMed Web of Science ®Google Scholar
• Davies S, Gold-von Simson G. Should infliximab be used as an adjuvant to IVIG in the treatment of children with Kawasaki disease who are at high risk for resistance to conventional therapy? Pediatr Cardiol 2013;34:1756.
   Google Scholar
• Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 2014;6736:62298–9.
   Google Scholar